GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh2 Group Ltd (NAS:FRES) » Definitions » COGS-to-Revenue

Fresh2 Group (Fresh2 Group) COGS-to-Revenue : 0.00 (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Fresh2 Group COGS-to-Revenue?

Fresh2 Group's Cost of Goods Sold for the three months ended in Jun. 2023 was $0.00 Mil. Its Revenue for the three months ended in Jun. 2023 was $0.00 Mil.

Fresh2 Group's COGS to Revenue for the three months ended in Jun. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Fresh2 Group's Gross Margin % for the three months ended in Jun. 2023 was N/A%.


Fresh2 Group COGS-to-Revenue Historical Data

The historical data trend for Fresh2 Group's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh2 Group COGS-to-Revenue Chart

Fresh2 Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
COGS-to-Revenue
Get a 7-Day Free Trial 0.55 0.56 0.37 0.32 0.31

Fresh2 Group Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 - 0.28 1.08 -

Fresh2 Group COGS-to-Revenue Calculation

Fresh2 Group's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.532 / 1.728
=0.31

Fresh2 Group's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fresh2 Group  (NAS:FRES) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Fresh2 Group's Gross Margin % for the three months ended in Jun. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Fresh2 Group COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Fresh2 Group's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresh2 Group (Fresh2 Group) Business Description

Traded in Other Exchanges
Address
650 5TH Avenue, Street 2416, NEW YORK, NY, USA, 10019-6108
Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.